Skip to main content
Log in

Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism

  • Pharmacogenetics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

In this pilot study, we attempted to determine the optimal dosage regimens of esomeprazole for treatment of GERD with minimal influence of the CYP2C19 polymorphism through a study of the pharmacokinetics and pharmacodynamics of esomeprazole given at 3 different dosage regimens with the same total daily dose.

Methods

Each of the 3genotypes of CYP2C19, homozygous extensive metabolizers (homEMs), heterozygous EMS (hetEMs), and poor metabolizers (PMs) were recruited in this clinical trial. Subjects were given a placebo followed by the administration of esomeprazole, at a dose of 40 mg once daily (40QD), 20 mg twice daily (20TD), or 10 mg 4 times daily (10Q4D) for 7 days. Twenty-four-hour and nocturnal intragastric pH and plasma esomeprazole concentrations were all determined on day 7.

Results

The pharmacokinetic parameters and dynamic characteristics differed among the 3 CYP2C19 genotype groups. With esomeprazole 40QD, gastric acid suppression was insufficient to achieve a therapeutic effect, while 20TD and 10Q4D were found to be effective in controlling both daytime and nocturnal gastric acidity for all 3 genotype groups.

Conclusions

It was confirmed that intragastric pH values and plasma esomeprazole concentrations potentially depended on the CYP2C19 genotype status for treatment with esomeprazole. Dosage regimens of divided doses of 20TD or 10Q4D esomeprazole yielded improved antisecretory effects with a minimal influence of CYP2C19 polymorphisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Orr WC (2005) Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. Eur J Gastroenterol Hepatol 17:113–120

    Article  PubMed  Google Scholar 

  2. Lindberg P, Keeling D, Fryklund J, Andersson T, Lundborg P, Carlsson E (2003) Esomeprazole - enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 17:481–488

    Article  PubMed  CAS  Google Scholar 

  3. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51(Suppl. 1):59–67

    Article  PubMed  Google Scholar 

  4. Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A et al (2001) Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16:1191–6

    Article  PubMed  CAS  Google Scholar 

  5. Peghini PL, Katz PO, Castell DO (1998) Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 115:1335–1339

    Article  PubMed  CAS  Google Scholar 

  6. Miner P Jr, Katz PO, Chen Y, Sostek M (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98:2616–2620

    Article  PubMed  CAS  Google Scholar 

  7. Thomson A, Claar-Nilsson C, Hasselgren G, Niazi M, Rohss K, Nyman L (2000) Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration. Gut 47(Suppl. 3):A63 (Abstract)

    Google Scholar 

  8. Lind T, Rydberg L, Kyleback A et al (2000) Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14:861–867

    Article  PubMed  CAS  Google Scholar 

  9. Röhss K, Hasselgren G, Hedenström H (2002) Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 47:954–958

    Article  PubMed  Google Scholar 

  10. Wilder-Smith C, Röhss K, Lundin C, Rydholm H (2000) Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 118:A22–23

    Article  Google Scholar 

  11. Wilder-Smith C, Claar-Nilsson C, Hasselgren G, Röhss K (2002) Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GORD. J Gastroenterol Hepatol 17(Suppl.):A612 (Abstract)

    Google Scholar 

  12. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB (2004) Intragastric acid suppression and pharmacokinelics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 20:399–406

    Article  PubMed  CAS  Google Scholar 

  13. Galmiche JP, Bruley S, Varannes DES, Ducrotte P, Sacher-Huvelin S, Vavasseur F et al (2004) Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 19:655–662

    Article  PubMed  CAS  Google Scholar 

  14. Peghini PL, Katz PO, Bracy NA, Castell DO (1998) Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763–767

    Article  PubMed  CAS  Google Scholar 

  15. Katz PO, Anderson C, Khoury R, Castell DO (1998) Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 12:1231–1234

    Article  PubMed  CAS  Google Scholar 

  16. Katsube T, Adachi K, Kawamura A, Amano K, Uchida Y, Watanabe M, Kinoshita Y (2000) Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14:1049–1056

    Article  PubMed  CAS  Google Scholar 

  17. Stedman CAM, Barclay ML (2000) Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963–978

    Article  PubMed  CAS  Google Scholar 

  18. Hassan-Alin M, Andersson T, Niazi M, Röhss K (2005) A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 60:779–784

    Article  PubMed  CAS  Google Scholar 

  19. Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S (2006) Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Therapeutics 79:144–1452

    Article  CAS  Google Scholar 

  20. Robinson M (2004) The pharmacodynamics and pharmacokinetics of proton pump inhibitors – overview and clinical implications. Aliment Pharmacol Ther 20:1–10

    Article  PubMed  CAS  Google Scholar 

  21. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai MO, Ishizaki T (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76:290–301

    Article  PubMed  CAS  Google Scholar 

  22. Sheu B-S, Kao A-W, Cheng H-C, Hunag S-F, Chen T-W, Lu C-C, Wu J-J (2005) Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 21:283–288

    Article  PubMed  CAS  Google Scholar 

  23. Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, Treiber G (2005) Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 78:627–634

    Article  PubMed  CAS  Google Scholar 

  24. De Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S- mephenytoin metabolism in humans. J Biol Chem 269:15419–15422

    PubMed  Google Scholar 

  25. Adachi K, Komazawa Y, Fujishiro H, Mihara T, Ono M, Yuki M et al (2003) Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subject: effects of different regimens. J Gastroenterol 38:830–835

    Article  PubMed  CAS  Google Scholar 

  26. Wagner JG (1979) Fundamentals of Clinical Pharmacokinetics, 2nd edn. Drug Intelligence Publications, Inc., Hamilton, IL, pp 36–7

    Google Scholar 

Download references

Acknowledgments

This study was sponsored by Taipei Medical University Hospital (95TMU-TMUH-06) and the National Science Council of ROC (NSC95–2320-B-038–012).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hsiu-O Ho.

Additional information

Horng-Yuan Lou and Chun-Chao Chang contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lou, HY., Chang, CC., Sheu, MT. et al. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol 65, 55–64 (2009). https://doi.org/10.1007/s00228-008-0552-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-008-0552-0

Keywords

Navigation